1. Baseline patient characteristics.
| Variables | n (%) | |
| Escalation cohort (N=19) | Expansion cohort (N=25) | |
| BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; RCC, renal clear cell carcinoma. | ||
| Age (year) | ||
|
45.3±13.2 | 57.2±9.2 |
| Median (range) | 50 (22−63) | 60 (36−76) |
| Sex | ||
| Male | 15 (78.9) | 18 (72.0) |
| Female | 4 (21.1) | 7 (28.0) |
| BMI (kg/m2) | ||
|
23.25±2.52 | 24.96±2.60 |
| Median (range) | 23.7 (18.7−25.9) | 25.5 (20.7−31.2) |
| ECOG performance status | ||
| 0 | 2 (10.5) | 4 (16.0) |
| 1 | 17 (89.5) | 21 (84.0) |
| Cancer type | ||
| RCC | 12 (63.2) | 25 (100) |
| Lung | 1 (5.2) | 0 (0) |
| Colorectal | 1 (5.2) | 0 (0) |
| Melanoma | 1 (5.2) | 0 (0) |
| Undifferentiated pleomorphic sarcoma | 1 (5.2) | 0 (0) |
| Primitive neuroectodermal tumor | 1 (5.2) | 0 (0) |
| Gastrointestinal stromal | 1 (5.2) | 0 (0) |
| Peritoneal desmoplastic small round cell tumor | 1 (5.2) | 0 (0) |
| Stage IV | 19 (100) | 25 (100) |
| Previous treatment | ||
| Surgery | 18 (94.7) | 20 (80.0) |
| Chemotherapy | 9 (47.4) | 6 (24.0) |
| Radiotherapy | 3 (15.8) | 5 (20.0) |
| Other treatment | 15 (78.9) | 19 (76.0) |